ImageneBio, Inc. IMA
We are a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. Our lead asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand ("OX40L"). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders, with initial evaluation in atopic dermatitis ("AD"). IMG-007 includes several features that we believe are important, differentiating attributes. First, IMG-007 is receptor-targeting, rather than ligand-targeting. Second, IMG-007 is non-T cell depleting: activated T cell signaling is attenuated, however T cells are not killed and depleted. Finally, IMG-007's half-life is approximately 5 weeks, which may allow for patient-and physician-friendly dosing schedules such as those currently being explored in our clinical program.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $800.0K | $3.5M | $9.2M | $15.6M | $31.0M | $9.2M | — |
| R&D | $28.5M | $32.1M | $59.7M | $64.3M | $47.1M | $44.8M | — |
| SG&A | $20.7M | $8.4M | $24.9M | $22.2M | $18.0M | $8.9M | — |
| Total operating expenses | $49.3M | $40.5M | $84.6M | $86.5M | $65.1M | $53.7M | — |
| Operating income | -$48.5M | -$37.0M | -$75.4M | -$70.9M | -$34.1M | -$44.5M | — |
| Pre-tax income | -$45.7M | -$36.6M | -$68.3M | -$68.8M | -$34.1M | — | — |
| Income tax | $350.0K | $13.0K | $162.0K | $0 | $0 | — | — |
| Net income | -$45.3M | -$36.6M | -$68.2M | -$68.8M | -$34.1M | -$44.3M | — |
| EPS, basic | -9.64 | -22.10 | -1.63 | -1.90 | -1.22 | — | — |
| EPS, diluted | -9.64 | -22.10 | -1.63 | -1.90 | -1.22 | -16.00 | — |
| Shares, diluted (wtd. avg.) | 4.9M | 1.2M | 41.7M | 36.2M | 28.0M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $94.5M | $12.1M | $15.3M | $60.8M | $233.1M | $163.4M | $82.1M |
| Short-term investments | $40.8M | $0 | $55.6M | $97.0M | — | — | — |
| Total current assets | $140.3M | $12.5M | $178.7M | $160.0M | $236.5M | $166.0M | — |
| Property, plant and equipment | $0 | $8.0K | $2.3M | $3.2M | $2.4M | $1.4M | — |
| Total assets | $153.0M | $15.9M | $192.1M | $172.3M | $247.9M | $168.4M | — |
| Accounts payable | $1.4M | $5.3M | $2.1M | $2.1M | $2.4M | $2.1M | — |
| Short-term debt | $0 | $7.5M | — | — | — | — | — |
| Total current liabilities | $11.2M | $17.2M | $14.2M | $21.5M | $27.2M | $28.3M | — |
| Total liabilities | $19.8M | $17.4M | $22.3M | $25.3M | $40.0M | $63.5M | — |
| Retained earnings | -$230.1M | -$179.9M | -$282.4M | -$214.2M | -$145.5M | -$111.3M | — |
| Total equity | $133.1M | -$160.6M | -$126.1M | $147.0M | $207.9M | -$101.0M | -$61.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$47.8M | -$21.3M | -$79.7M | -$74.1M | -$60.3M | -$37.8M | — |
| Depreciation and amortisation | $400.0K | $1.1M | $1.0M | $751.0K | $544.0K | $300.0K | — |
| Stock-based compensation | $15.4M | $0 | $7.6M | $7.5M | $5.2M | $1.8M | — |
| Capital expenditure | — | — | $414.0K | $1.4M | $1.8M | $766.0K | — |
| Investing cash flow | -$5.8M | $11.1M | $64.1M | -$99.3M | -$1.8M | $2.9M | — |
| Financing cash flow | $135.5M | $6.9M | $76.0M | $1.1M | $131.7M | $116.2M | — |
| Buybacks | — | — | $663.0K | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-099434.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $9.2M | $31.0M | $15.6M | $9.2M | $3.5M | $800.0K |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$44.3M | -$34.1M | -$68.8M | -$68.2M | -$36.6M | -$45.3M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Officer or director change Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |